<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Neurophysiol</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Neurophysiol</journal-id><journal-id journal-id-type="publisher-id">jcnp</journal-id><journal-title-group><journal-title>Journal of Clinical Neurophysiology</journal-title></journal-title-group><issn pub-type="ppub">0736-0258</issn><issn pub-type="epub">1537-1603</issn><publisher><publisher-name>Journal of Clinical Neurophysiology</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39051913</article-id><article-id pub-id-type="pmc">PMC11864052</article-id>
<article-id pub-id-type="publisher-id">JCNP-D-24-00011</article-id><article-id pub-id-type="doi">10.1097/WNP.0000000000001107</article-id><article-id pub-id-type="art-access-id">00009</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Visual Electroencephalography Assessment in the Diagnosis and Prognosis of Cognitive Disorders</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6892-9719</contrib-id><name><surname>Michels</surname><given-names>Daan M.</given-names></name><email>d.michels@erasmusmc.nl</email><xref rid="aff1" ref-type="aff">*</xref><xref rid="aff3" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>van Marum</surname><given-names>Sjoerd</given-names></name><email>s.vanmarum@hagaziekenhuis.nl</email><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Arends</surname><given-names>Samuel</given-names></name><xref rid="aff1" ref-type="aff">*</xref><xref rid="aff3" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Tavy</surname><given-names>D. L. J.</given-names></name><xref rid="aff1" ref-type="aff">*</xref><email>tavy@ziggo.nl</email></contrib><contrib contrib-type="author"><name><surname>Wirtz</surname><given-names>Paul W.</given-names></name><email>p.wirtz@hagaziekenhuis.nl</email><xref rid="aff1" ref-type="aff">*</xref></contrib><contrib contrib-type="author"><name><surname>de Bruijn</surname><given-names>Bas S. F. T. M.</given-names></name><email>s.debruijn@hagaziekenhuis.nl</email><xref rid="aff1" ref-type="aff">*</xref></contrib><aff id="aff1"><label>*</label>Department of Neurology and Clinical Neurophysiology, Haga Hospital, The Hague, <country>the Netherlands</country>;</aff><aff id="aff2"><label>&#x02021;</label>Medical Faculty, LUMC, Leiden, <country>the Netherlands</country>; and</aff><aff id="aff3"><label>&#x02020;</label>Department of Neurology, Erasmus MC, Rotterdam, <country>the Netherlands</country>.</aff></contrib-group><author-notes><corresp>Address correspondence and reprint requests to S. Arends, MD, Department of Neurology and Clinical Neurophysiology, Haga Hospital, Els Borst-Eilersplein 275, The Hague 2545 AA, The Netherlands; e-mail: <email>s.arends@erasmusmc.nl</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>25</day><month>7</month><year>2024</year></pub-date><volume>42</volume><issue>3</issue><fpage>243</fpage><lpage>250</lpage><permissions><copyright-statement>Copyright &#x000a9; 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Clinical Neurophysiology Society.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CCBY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="jcnp-42-243.pdf"/><abstract><sec><title>Purpose:</title><p>Electroencephalography (EEG) is a noninvasive diagnostic tool that can be of diagnostic value in patients with cognitive disorders. In recent years, increasing emphasis has been on quantitative EEG analysis, which is not easily accessible in clinical practice. The aim of this study was to assess the diagnostic and prognostic value of visual EEG assessment to distinguish different causes of cognitive disorders.</p></sec><sec><title>Methods:</title><p>Patients with cognitive disorders from a specialized memory clinic cohort underwent routine workup including EEG, neuropsychological testing and brain imaging. Electroencephalography parameters including posterior dominant rhythm, background activity, and response to photic stimulation (intermittent photic stimulation) were visually scored. Final diagnosis was made by an expert panel.</p></sec><sec><title>Results:</title><p>A total of 501 patients were included and underwent full diagnostic workup. One hundred eighty-three patients had dementia (111 Alzheimer disease, 30 vascular dementia, 15 frontotemporal dementia, and 9 dementia with Lewy bodies), 66 patients were classified as mild cognitive impairment, and in 176, no neurologic diagnosis was made. Electroencephalography was abnormal in 60% to 90% of patients with mild cognitive impairment and dementia, most profoundly in dementia with Lewy bodies and Alzheimer disease, while frontotemporal dementia had normal EEG relatively often. Only 30% of those without neurologic diagnosis had EEG abnormalities, mainly a diminished intermittent photic stimulation response. Odds ratio of conversion to dementia was 6.1 [1.5&#x02013;24.7] for patients with mild cognitive impairment with abnormal background activity, compared with those with normal EEG.</p></sec><sec><title>Conclusions:</title><p>Visual EEG assessment has diagnostic and prognostic value in clinical practice to distinguish patients with memory complaints without underlying neurologic disorder from patients with mild cognitive impairment or dementia.</p></sec></abstract><kwd-group><title>Key Words:</title><kwd>Electroencephalography</kwd><kwd>Dementia</kwd><kwd>Alzheimer disease</kwd><kwd>Vascular dementia</kwd><kwd>Frontotemporal dementia</kwd><kwd>Dementia with Lewy bodies</kwd><kwd>Mild cognitive impairment</kwd><kwd>Intermittent photic stimulation</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Dementia is a global health care problem of increasing magnitude. In 2019, an estimated 57 million people worldwide were living with dementia, and this number will likely increase to 150 million by 2050.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Alzheimer disease (AD) is the most prevalent form of dementia (70% of all cases), followed by vascular dementia (VD) and dementia with Lewy Bodies (DLB) both accounting for 5% to 10%.<sup><xref rid="R2" ref-type="bibr">2</xref></sup></p><p>Neuropsychiatric symptoms and cognitive disorders (e.g., disorders of executive functions, information processing, and verbal memory) are frequently present in both dementia and primary psychiatric diseases.<sup><xref rid="R3" ref-type="bibr">3</xref>&#x02013;<xref rid="R5" ref-type="bibr">5</xref></sup> Distinction between early stage dementia and other causes of cognitive disorders (such as depression or temporal lobe epilepsy) can be difficult in patients with mild cognitive impairment (MCI). This highlights the need for additional biomarkers to facilitate early patient selection for trials and potential new treatment options.</p><p>Electroencephalography (EEG) is a widely accessible, inexpensive, and noninvasive diagnostic instrument. The diagnostic value have been investigated extensively in a variety of neurodegenerative disorders, such as AD, Parkinson disease, and DLB.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup> Electroencephalography can be of additional value in distinguishing cases of DLB and AD from healthy controls.<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref></sup> Especially in DLB, EEG abnormalities such as slowing of posterior dominant rhythm (PDR) and presence of frontal intermittent rhythmic delta activity can support the diagnosis in the prodromal phase of disease, when only mild cognitive complaints are present.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> In DLB diagnostic criteria, the presence of frontal intermittent rhythmic delta activity has been incorporated as a supportive biomarker.<sup><xref rid="R11" ref-type="bibr">11</xref></sup></p><p>The grand total EEG score, a published visual EEG assessment scale to determine disease severity, was significantly related to diagnosis in patients with AD compared with healthy controls, and in DLB compared with patients with AD.<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R12" ref-type="bibr">12</xref></sup></p><p>Intermittent photic stimulation (IPS) is a commonly performed procedure as part of standard EEG recording.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> Besides the usage of IPS to detect photosensitivity in epilepsies, suppression of the PDR by IPS is a measure of brain reactivity to stimuli. Previous studies have demonstrated reduced reactivity to IPS in patients with AD compared with healthy controls, but little is known about the value of IPS in other forms of dementia, and potential prognostic value related to symptom progression.<sup><xref rid="R14" ref-type="bibr">14</xref>&#x02013;<xref rid="R17" ref-type="bibr">17</xref></sup></p><p>The aims of this study were (1) to describe the EEG characteristics in a large cohort from our specialized memory clinic; (2) to assess the diagnostic value of visual EEG assessment and the additional value of IPS, in discriminating different causes of cognitive disorders; and (3) to determine the ability of IPS to discriminate between patients with MCI with and without progression to dementia.</p><sec sec-type="methods" id="s1"><title>METHODS</title><sec id="s1-1"><title>Study Population</title><p>Patients visiting a specialized memory clinic from the neurology department of a large general hospital in The Hague, The Netherlands, were consecutively included from visits between 2016 and 2021. All patients showing deficits on bedside cognitive screening including mini mental state examination, Montreal cognitive assessment, and/or frontal assessment battery were included and underwent diagnostic workup. The diagnostic workup consisted of standardized neuropsychological tests, structural brain imaging (MRI when possible, otherwise computed tomography), laboratory testing (blood cell count; renal, liver, and thyroid function; and vitamins and glucose levels), and a resting state EEG. Additional tests were performed based on clinical indication in individual cases, including nuclear imaging (Fluorodeoxyglucose, amyloid or 18F-N-(3-fluoropropyl)-2&#x003b2;-carboxymethoxy-3&#x003b2;-(4-iodophenyl) nortropane-positron emission tomography (FDG-PET, amyloid-PET, or FP-CIT)) or cerebrospinal fluid analysis (A&#x003b2;-42, tau and p-tau).</p><p>Final diagnosis was made by an expert panel consisting of multiple neurologists specializing in cognitive disorders, a neuropsychologist, radiologist, and clinical neurophysiologist. All diagnoses of neurodegenerative dementia were based on current international diagnostic criteria.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> Electroencephalography was routinely performed to rule out temporal lobe epilepsy as a potential cause of cognitive disorders. The EEG was not part of the diagnostic criteria used, except for the minor role of supportive criterion in DLB.</p><p>Mild cognitive impairment was defined as cognitive disorders on one or more cognitive domains, but not fulfilling the diagnostic criteria for dementia (i.e., no interference with activities of daily living). For the purpose of this study, cognitive disorders due to other causes, such as epilepsy, psychiatric disorders, or traumatic brain injury, were not labelled MCI but according to the suspected underlying cause.</p></sec><sec id="s1-2"><title>Protocol Approval and Consent</title><p>The study was approved by the regional medical ethics committee of the Haga hospital.</p></sec><sec id="s1-3"><title>EEG Recording</title><p>All participants underwent a 20-minute resting-state EEG (BrainRT version 4.04, O.S.G BV, Belgium). A total of 23 scalp electrodes were placed according to the international 10 to 20 system at the following locations: FP2, FP1, F8, F7, F4, F3, PG2, PG1, A2, A1, T4, T3, C4, C3, T6, T5, P4, P3, O2, O1, Fz, Cz, and Pz. High-frequency and low-frequency pass filters were set at 70 and 0.27 Hz, respectively. Standard recording protocol included alternating between eyes open and closed, hyperventilation during 3 minutes, and IPS. Intermittent photic stimulation was performed according to international standards,<sup><xref rid="R13" ref-type="bibr">13</xref></sup> using 4 to 30 Hz IPS frequencies. Patients were seated upright in a slightly darkened room with eyes open. The same flash stimulator and setup was used throughout the entire study period.</p></sec><sec id="s1-4"><title>EEG Assessment</title><p>Electroencephalographies were scored based on consensus by two reviewers. To determine interobserver agreement, a third clinical neurophysiologist reviewed a subset of EEGs. Assessment was performed both visually and quantitatively, using power spectral density measurement.</p><p>Posterior dominant rhythm and screening for diffuse slow background activity (BA) were assessed in at least three artefact-free epochs of sufficient length (at least 5 seconds) using a bipolar montage (double banana). Posterior dominant rhythm was defined as the dominant rhythmic activity over the posterior regions and scored for frequency (Hz) and reactivity (present/absent). Background activity was scored on a four-point scale based on the grand total EEG score previously described by Jonkman et al.<sup><xref rid="R18" ref-type="bibr">18</xref></sup>: 0 = normal, 1 = intermittent theta activity, 2 = profound theta and some delta activity, and 3 = profound delta activity. The presence of frontal intermittent rhythmic delta activity was scored (present/absent). Focal abnormalities and reaction to IPS were scored using a common average reference or source derivation montage. Abnormal IPS response was defined as the absence of a distinguishable frequency peak on power spectral density, corresponding to the frequency presented with IPS, in at least half of all presented frequencies. Reactivity at subharmonic or supraharmonic frequencies was deemed a physiological variant. A diminished response was scored when a frequency peak was visible, but with power than the BA (in &#x000b5;V<sup>2</sup>/Hz).</p></sec><sec id="s1-5"><title>Statistical Analysis</title><p>IBM SPSS statistics, version 28, was used for statistical analysis. Clinical and EEG parameters were assessed with &#x003c7;<sup>2</sup> test or Kruskal&#x02013;Wallis test for categorical data. Ordinal and (semi-)continuous data were analyzed with analysis of variance for normally distributed data. A <italic toggle="yes">P</italic>-value of &#x0003c;0.05 was considered statistically significant.</p><p>Cohen &#x003ba; was calculated to determine interobserver agreement.</p><p>A multivariate logistic regression model was constructed to determine the prognostic value of EEG parameters for final diagnosis, and likelihood ratios were calculated to distinguish between dementia syndromes and nonneurologic disorders.</p></sec></sec><sec sec-type="results" id="s2"><title>RESULTS</title><sec id="s2-1"><title>Patient Characteristics</title><p>Between 2016 and 2022, a total of 1,369 patients visited the outpatient clinic for cognitive complaints. After screening, a total of 506 patients received a full diagnostic workup. Of these, five patients were excluded because the EEG data could not be retrieved. Finally, 501 patients were included in this study. The baseline characteristics are summarized in Table <xref rid="T1" ref-type="table">1</xref>.</p><table-wrap position="float" id="T1"><label>TABLE 1.</label><caption><p>Patient Characteristics of the Overall Population and of Important Subgroups</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Total (<italic toggle="yes">N</italic> = 501)</td><td rowspan="1" colspan="1">No Neurologic Disorder (<italic toggle="yes">N</italic> = 176)</td><td rowspan="1" colspan="1">MCI (<italic toggle="yes">N</italic> = 66)</td><td rowspan="1" colspan="1">AD (<italic toggle="yes">N</italic> = 111)</td><td rowspan="1" colspan="1">VD (<italic toggle="yes">N</italic> = 30)</td><td rowspan="1" colspan="1">AD/VD (<italic toggle="yes">N</italic> = 18)</td><td rowspan="1" colspan="1">FTD (<italic toggle="yes">N</italic> = 15)</td><td rowspan="1" colspan="1">DLB (<italic toggle="yes">N</italic> = 9)</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age, years (SD)</td><td rowspan="1" colspan="1">67 (11.8)</td><td rowspan="1" colspan="1">60 (11.9)</td><td rowspan="1" colspan="1">71 (7.8)</td><td rowspan="1" colspan="1">73 (8.0)</td><td rowspan="1" colspan="1">71 (7.2)</td><td rowspan="1" colspan="1">75 (4.9)</td><td rowspan="1" colspan="1">71 (6.9)</td><td rowspan="1" colspan="1">70 (7.3)</td></tr><tr><td colspan="9" rowspan="1">Sex (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Male</td><td rowspan="1" colspan="1">281 (56.1)</td><td rowspan="1" colspan="1">94 (53.4)</td><td rowspan="1" colspan="1">38 (57.6)</td><td rowspan="1" colspan="1">49 (44.1)</td><td rowspan="1" colspan="1">22 (73.3)</td><td rowspan="1" colspan="1">8 (44.4)</td><td rowspan="1" colspan="1">9 (57.1)</td><td rowspan="1" colspan="1">7 (77.8)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Female</td><td rowspan="1" colspan="1">220 (43.9)</td><td rowspan="1" colspan="1">82 (46.6)</td><td rowspan="1" colspan="1">28 (42.4)</td><td rowspan="1" colspan="1">62 (55.9)</td><td rowspan="1" colspan="1">8 (26.7)</td><td rowspan="1" colspan="1">10 (55.6)</td><td rowspan="1" colspan="1">6 (42.9)</td><td rowspan="1" colspan="1">2 (22.2)</td></tr><tr><td rowspan="1" colspan="1">MMSE (SD, IQR)</td><td rowspan="1" colspan="1">25 (4.1, 22&#x02013;28)</td><td rowspan="1" colspan="1">27 (4.1, 25&#x02013;29)</td><td rowspan="1" colspan="1">25 (3.0, 23&#x02013;26)</td><td rowspan="1" colspan="1">23 (4.2, 20&#x02013;26)</td><td rowspan="1" colspan="1">25 (5.0, 22&#x02013;28)</td><td rowspan="1" colspan="1">24 (3.7, 20&#x02013;26)</td><td rowspan="1" colspan="1">25 (2.7, 23&#x02013;28)</td><td rowspan="1" colspan="1">24 (2.6, 23&#x02013;27)</td></tr><tr><td rowspan="1" colspan="1">MoCA (SD, IQR)</td><td rowspan="1" colspan="1">21 (5.1, 17&#x02013;24)</td><td rowspan="1" colspan="1">23 (5.4, 20&#x02013;27)</td><td rowspan="1" colspan="1">22 (3.8, 20&#x02013;24)</td><td rowspan="1" colspan="1">18 (3.4, 16&#x02013;20)</td><td rowspan="1" colspan="1">21 (2.7, 20&#x02013;24)</td><td rowspan="1" colspan="1">15 (4.0, 11&#x02013;17)</td><td rowspan="1" colspan="1">22 (7.1, N/A)</td><td rowspan="1" colspan="1">16 (7.1, N/A)</td></tr><tr><td rowspan="1" colspan="1">FAB (SD, IQR)</td><td rowspan="1" colspan="1">14 (3.4, 11&#x02013;16)</td><td rowspan="1" colspan="1">15 (3.2, 13&#x02013;17)</td><td rowspan="1" colspan="1">14 (3.6, 11&#x02013;16)</td><td rowspan="1" colspan="1">12 (3.4, 9&#x02013;14)</td><td rowspan="1" colspan="1">13 (4.0, 10&#x02013;14)</td><td rowspan="1" colspan="1">12 (2.7, 10&#x02013;14)</td><td rowspan="1" colspan="1">14 (2.4, 12&#x02013;15)</td><td rowspan="1" colspan="1">11 (3.0, 8&#x02013;13)</td></tr><tr><td colspan="9" rowspan="1">Current substance abuse</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Alcohol (%)</td><td rowspan="1" colspan="1">49 (9.8)</td><td rowspan="1" colspan="1">9 (5.1)</td><td rowspan="1" colspan="1">11 (16.7)</td><td rowspan="1" colspan="1">7 (6.3)</td><td rowspan="1" colspan="1">6 (20.0)</td><td rowspan="1" colspan="1">2 (11.1)</td><td rowspan="1" colspan="1">1 (6.7)</td><td rowspan="1" colspan="1">&#x02014;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Drugs (%)</td><td rowspan="1" colspan="1">7 (1.4)</td><td rowspan="1" colspan="1">3 (1.7)</td><td rowspan="1" colspan="1">1 (1.5)</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td></tr><tr><td colspan="9" rowspan="1">Medication affecting EEG (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Benzodiazepines</td><td rowspan="1" colspan="1">33 (6.6)</td><td rowspan="1" colspan="1">11 (6.3)</td><td rowspan="1" colspan="1">5 (7.6)</td><td rowspan="1" colspan="1">6 (5.4)</td><td rowspan="1" colspan="1">1 (3.3)</td><td rowspan="1" colspan="1">2 (11.1)</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">1 (11.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Antiseizure medication</td><td rowspan="1" colspan="1">26 (5.2)</td><td rowspan="1" colspan="1">9 (5.1)</td><td rowspan="1" colspan="1">4 (6.1)</td><td rowspan="1" colspan="1">1 (0.9)</td><td rowspan="1" colspan="1">2 (6.7)</td><td rowspan="1" colspan="1">1 (5.6)</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">1 (11.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Antipsychotics</td><td rowspan="1" colspan="1">7 (1.4)</td><td rowspan="1" colspan="1">4 (2.3)</td><td rowspan="1" colspan="1">1 (1.5)</td><td rowspan="1" colspan="1">1 (0.9)</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">1 (6.7)</td><td rowspan="1" colspan="1">&#x02014;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Antidepressants</td><td rowspan="1" colspan="1">50 (10.0)</td><td rowspan="1" colspan="1">31 (17.6)</td><td rowspan="1" colspan="1">2 (3.0)</td><td rowspan="1" colspan="1">9 (8.1)</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">2 (11.1)</td><td rowspan="1" colspan="1">2 (13.3)</td><td rowspan="1" colspan="1">&#x02014;</td></tr><tr><td colspan="9" rowspan="1">EEG characteristics</td></tr><tr><td rowspan="1" colspan="1">&#x02003;PDR peak frequency, Hz (SD, IQR)</td><td rowspan="1" colspan="1">9.3 (1.3, 8.5&#x02013;10.0)</td><td rowspan="1" colspan="1">9.8 (1.2, 9.0&#x02013;10.5)</td><td rowspan="1" colspan="1">9.1 (1.2, 8.3&#x02013;10.0)</td><td rowspan="1" colspan="1">8.8 (1.4, 7.8&#x02013;10.0)</td><td rowspan="1" colspan="1">8.9 (0.9, 8.4&#x02013;9.5)</td><td rowspan="1" colspan="1">8.4 (1.2, 7.6&#x02013;9.4)</td><td rowspan="1" colspan="1">9.7 (0.9, 9.1&#x02013;10.4)</td><td rowspan="1" colspan="1">7.6 (1.1, 6.7&#x02013;8.7)</td></tr><tr><td colspan="9" rowspan="1">&#x02003;Background activity (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Normal</td><td rowspan="1" colspan="1">339 (67.7)</td><td rowspan="1" colspan="1">154 (87.5)</td><td rowspan="1" colspan="1">40 (60.6)</td><td rowspan="1" colspan="1">53 (47.7)</td><td rowspan="1" colspan="1">18 (60.0)</td><td rowspan="1" colspan="1">6 (33.3)</td><td rowspan="1" colspan="1">11 (73.3)</td><td rowspan="1" colspan="1">1 (11.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Mild slowing</td><td rowspan="1" colspan="1">121 (24.2)</td><td rowspan="1" colspan="1">20 (11.4)</td><td rowspan="1" colspan="1">22 (33.3)</td><td rowspan="1" colspan="1">42 (37.8)</td><td rowspan="1" colspan="1">8 (26.7)</td><td rowspan="1" colspan="1">9 (50)</td><td rowspan="1" colspan="1">4 (26.7)</td><td rowspan="1" colspan="1">4 (44.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Moderate slowing</td><td rowspan="1" colspan="1">34 (6.6)</td><td rowspan="1" colspan="1">1 (0.6)</td><td rowspan="1" colspan="1">4 (6.1)</td><td rowspan="1" colspan="1">15 (13.5)</td><td rowspan="1" colspan="1">3 (10)</td><td rowspan="1" colspan="1">3 (16.7)</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">3 (33.3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Severe slowing/absent</td><td rowspan="1" colspan="1">4 (0.8)</td><td rowspan="1" colspan="1">1 (0.6)</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">1 (11.1)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;FIRDA (%)</td><td rowspan="1" colspan="1">56 (11.2)</td><td rowspan="1" colspan="1">8 (4.5)</td><td rowspan="1" colspan="1">6 (9.1)</td><td rowspan="1" colspan="1">22 (19.8)</td><td rowspan="1" colspan="1">4 (13.3)</td><td rowspan="1" colspan="1">3 (16.7)</td><td rowspan="1" colspan="1">1 (7.1)</td><td rowspan="1" colspan="1">6 (66.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Epileptiform discharges (%)</td><td rowspan="1" colspan="1">36 (7.2)</td><td rowspan="1" colspan="1">12 (6.8)</td><td rowspan="1" colspan="1">2 (4.4)</td><td rowspan="1" colspan="1">6 (5.4)</td><td rowspan="1" colspan="1">2 (6.7)</td><td rowspan="1" colspan="1">1 (5.6)</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Generalized</td><td rowspan="1" colspan="1">3 (0.6)</td><td rowspan="1" colspan="1">1 (0.6)</td><td rowspan="1" colspan="1">1 (1.5)</td><td rowspan="1" colspan="1">1 (0.9)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td colspan="9" rowspan="1">&#x02003;Focal</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Frontal</td><td rowspan="1" colspan="1">24 (5.4)</td><td rowspan="1" colspan="1">6 (3.4)</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">5 (4.5)</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">1 (5.6)</td><td rowspan="1" colspan="1">1 (6.7)</td><td rowspan="1" colspan="1">&#x02014;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Temporal</td><td rowspan="1" colspan="1">32 (6.4)</td><td rowspan="1" colspan="1">9 (5.1)</td><td rowspan="1" colspan="1">1 (1.5)</td><td rowspan="1" colspan="1">5 (4.5)</td><td rowspan="1" colspan="1">2 (6.7)</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">1 (6.7)</td><td rowspan="1" colspan="1">&#x02014;</td></tr><tr><td colspan="9" rowspan="1">&#x02003;IPS reactivity (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Normal</td><td rowspan="1" colspan="1">298 (59.5)</td><td rowspan="1" colspan="1">124 (70.5)</td><td rowspan="1" colspan="1">32 (48.5)</td><td rowspan="1" colspan="1">60 (54.1)</td><td rowspan="1" colspan="1">17 (56.7)</td><td rowspan="1" colspan="1">9 (50.0)</td><td rowspan="1" colspan="1">3 (33.3%)</td><td rowspan="1" colspan="1">8 (53.3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Diminished</td><td rowspan="1" colspan="1">115 (23.0)</td><td rowspan="1" colspan="1">31 (17.6)</td><td rowspan="1" colspan="1">23 (34.8)</td><td rowspan="1" colspan="1">29 (26.1)</td><td rowspan="1" colspan="1">6 (20.0)</td><td rowspan="1" colspan="1">5 (27.8)</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">2 (13.3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;Absent</td><td rowspan="1" colspan="1">79 (15.8)</td><td rowspan="1" colspan="1">16 (9.1)</td><td rowspan="1" colspan="1">9 (13.6)</td><td rowspan="1" colspan="1">22 (19.8)</td><td rowspan="1" colspan="1">7 (23.3)</td><td rowspan="1" colspan="1">4 (22.2)</td><td rowspan="1" colspan="1">6 (66.7%)</td><td rowspan="1" colspan="1">5 (33.3)</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Percentages may not add up to 100% due to the exclusion of minor subgroups from this table.</p></fn><fn fn-type="other"><p>AD, Alzheimer disease; DLB, dementia with Lewy bodies; EEG, electroencephalography; FAB, frontal assessment battery; FIRDA, frontal intermittent rhythmic delta activity; FTD, frontotemporal dementia; IPS, intermittent photic stimulation; IQR, interquartile range; MCI, mild cognitive impairment; MMSE, mini mental-state examination; MoCA, montreal cognitive assessment; PDR, posterior dominant rhythm; VD, vascular dementia.</p></fn></table-wrap-foot></table-wrap><p>A total of 183 patients fulfilled the clinical criteria for dementia, specifically AD in 111 patients (22.2% of the total population), VD in 30 patients (6%), a combination of AD and VD in 18 cases (3.6%), frontotemporal dementia (FTD) in 15 cases (3%), and DLB in 9 (1.8%). In total, 66 patients (13.2%) had a possible neurodegenerative disorder but did not fulfil the criteria for dementia and were therefore classified as MCI. Patients without evidence of a neurologic condition were significantly younger than both patients with MCI and dementia (mean age 60 [SD 11.9] vs. 72 [SD 7.7] years, <italic toggle="yes">P</italic> &#x0003c; 0.001).</p><p>Other causes of cognitive disorders were toxic encephalopathy due to the (over)use of alcohol, drugs or medication (4%), structural brain abnormalities (3.8%), and temporal lobe epilepsy (1.2%). In 176 patients (35.1%), no underlying condition (neurologic or otherwise) was diagnosed.</p></sec><sec id="s2-2"><title>EEG Characteristics</title><p>Figures <xref rid="F1" ref-type="fig">1</xref>A&#x02013;<xref rid="F1" ref-type="fig">1</xref>C show an overview of the BA, PDR, and IPS response for each specified subgroup. Cohen &#x003ba; was 0.62, indicating substantial interobserver agreement between EEG raters. Background activity was normal in 88% of those without a neurologic condition, compared with 47% of patients with AD, 39% of patients with AD/VD, and 11% of patients with DLB. All epileptic patients had normal BA (Fig. <xref rid="F1" ref-type="fig">1</xref>A). Posterior dominant rhythm peak frequency was significantly higher for those without neurologic disorder, but also for patients with epilepsy and FTD, compared with other neurodegenerative disorders (Fig. <xref rid="F1" ref-type="fig">1</xref>B). Aside from FTD, no significant differences in BA and PDR frequency between subgroups of dementia were observed.</p><fig position="float" id="F1"><label>FIG. 1.</label><caption><p><bold>A</bold>, Percentage of patients with abnormal BA per subgroup. <bold>B</bold>, Posterior dominant rhythm peak frequency per subgroup. *<italic toggle="yes">P</italic> &#x0003c; 0.05. <bold>C</bold>, Percentage of patients with abnormal IPS response per subgroup. AD, Alzheimer disease; BA, background activity; DLB, dementia with Lewy bodies; FTD, frontotemporal dementia; IPS, intermittent photic stimulation; MCI, mild cognitive impairment; VD, vascular dementia.</p></caption><graphic xlink:href="jcnp-42-243-g001" position="float"/></fig><p>Response to IPS either diminished or absent in approximately 50% to 66% of patients with MCI and dementia, while this was only the case for 27% of those with no neurologic disorder. In contrast to BA, which is relatively normal in patients with FTD, IPS response was absent in 67%, compared with around 20% to 33% of patients with AD, AD/VD, and DLB (Fig. <xref rid="F1" ref-type="fig">1</xref>C).</p><p>When BA and IPS response were combined, patients with neurodegenerative disease had more abnormalities than those with no neurologic disorder or epilepsy (60% to 65% vs. 35% to 40%, respectively). The most EEG abnormalities (80% to 90%) were seen in patients with combined AD/VD and DLB (Fig. <xref rid="F2" ref-type="fig">2</xref>).</p><fig position="float" id="F2"><label>FIG. 2.</label><caption><p>Percentage of patients with any EEG abnormality per subgroup. AD, Alzheimer disease; DLB, dementia with Lewy bodies; EEG, electroencephalography; FTD, frontotemporal dementia; IPS, intermittent photic simulation; MCI, mild cognitive impairment; VD, vascular dementia.</p></caption><graphic xlink:href="jcnp-42-243-g002" position="float"/></fig></sec><sec id="s2-3"><title>Diagnostic Classification Based on EEG</title><p>The predictive value of different EEG parameters was assessed using a backward logistic regression model, corrected for age and sex. Odds ratios for a diagnosis of MCI and AD, compared with no neurologic disorder, are summarized in Table <xref rid="T2" ref-type="table">2</xref>. Abnormal BA (OR 3.7 [95% CI: 2.2&#x02013;6.2], <italic toggle="yes">P</italic> &#x0003c; 0.001), presence of frontal intermittent rhythmic delta activity (OR 4.4 [95% CI: 1.7&#x02013;11.2], <italic toggle="yes">P</italic> = 0.002), and abnormal response to IPS were all independent predictors of AD. For MCI, only abnormal BA (OR 2.2 [95% CI: 1.2&#x02013;3.9], <italic toggle="yes">P</italic> = 0.008) was a statistically significant predictor.</p><table-wrap position="float" id="T2"><label>TABLE 2.</label><caption><p>Relationship Between EEG Parameters and Clinical Diagnosis of MCI (<italic toggle="yes">n</italic> = 66) or AD (<italic toggle="yes">N</italic> = 128) Compared With No Neurologic Disorder (<italic toggle="yes">n</italic> = 176), Based on Backward Logistic Regression, Adjusted for Age and Sex</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1">EEG Parameter</td><td rowspan="1" colspan="1">OR for MCI</td><td rowspan="1" colspan="1">95% CI</td><td rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</td><td rowspan="1" colspan="1">OR for AD</td><td rowspan="1" colspan="1">95% CI</td><td rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Abnormal background activity</td><td align="char" char="." rowspan="1" colspan="1">2.2</td><td align="char" char="ndash" rowspan="1" colspan="1">1.2&#x02013;3.9</td><td align="char" char="." rowspan="1" colspan="1">0.008</td><td align="char" char="." rowspan="1" colspan="1">3.7</td><td align="char" char="ndash" rowspan="1" colspan="1">2.2&#x02013;6.2</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Presence of FIRDA</td><td align="char" char="." rowspan="1" colspan="1">1.7</td><td align="char" char="ndash" rowspan="1" colspan="1">0.5&#x02013;5.3</td><td align="char" char="." rowspan="1" colspan="1">0.39</td><td align="char" char="." rowspan="1" colspan="1">4.4</td><td align="char" char="ndash" rowspan="1" colspan="1">1.7&#x02013;11.2</td><td align="char" char="." rowspan="1" colspan="1">0.002</td></tr><tr><td rowspan="1" colspan="1">Abnormal response to IPS</td><td align="char" char="." rowspan="1" colspan="1">1.4</td><td align="char" char="ndash" rowspan="1" colspan="1">0.9&#x02013;2.2</td><td align="char" char="." rowspan="1" colspan="1">0.134</td><td align="char" char="." rowspan="1" colspan="1">1.5</td><td align="char" char="ndash" rowspan="1" colspan="1">1.0&#x02013;2.2</td><td align="char" char="." rowspan="1" colspan="1">0.038</td></tr><tr><td rowspan="1" colspan="1">Any epileptic activity</td><td align="char" char="." rowspan="1" colspan="1">2.5</td><td align="char" char="ndash" rowspan="1" colspan="1">0.5&#x02013;12.0</td><td align="char" char="." rowspan="1" colspan="1">0.26</td><td align="char" char="." rowspan="1" colspan="1">1.3</td><td align="char" char="ndash" rowspan="1" colspan="1">0.4&#x02013;3.8</td><td align="char" char="." rowspan="1" colspan="1">0.67</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>AD, Alzheimer disease; CI, confidence interval; EEG, electroencephalography; FIRDA, frontal intermittent rhythmic delta activity; MCI, mild cognitive impairment; OR, odds ratio.</p></fn></table-wrap-foot></table-wrap><p>The diagnostic value of abnormal BA for AD and &#x0201c;any dementia&#x0201d; was calculated based on 2 &#x000d7; 2 tables, comparing with those without neurologic disorders (Tables <xref rid="T3" ref-type="table">3</xref> and <xref rid="T4" ref-type="table">4</xref>). Sensitivity and specificity were 0.52 and 0.88 for AD, and 0.51 and 0.88 for &#x0201c;any dementia.&#x0201d; These result in positive likelihood ratios of 4.15 (95% CI: 2.70&#x02013;6.38) (AD) and 4.02 (95% CI: 2.68&#x02013;6.17) (any dementia), when abnormal BA is present. Negative likelihood ratios were 0.55 (95% CI: 0.45&#x02013;0.67) and 0.56 (95% CI: 0.48&#x02013;0.66), respectively.</p><table-wrap position="float" id="T3"><label>TABLE 3.</label><caption><p>Test Characteristics of Abnormal Background Activity for Diagnosing AD</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">AD</td><td rowspan="1" colspan="1">Non Neurologic Disorder</td><td rowspan="1" colspan="1">Total</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Background activity abnormal</td><td align="char" char="." rowspan="1" colspan="1">57</td><td align="char" char="." rowspan="1" colspan="1">22</td><td align="char" char="." rowspan="1" colspan="1">79</td></tr><tr><td rowspan="1" colspan="1">Background activity normal</td><td align="char" char="." rowspan="1" colspan="1">53</td><td align="char" char="." rowspan="1" colspan="1">154</td><td align="char" char="." rowspan="1" colspan="1">207</td></tr><tr><td rowspan="1" colspan="1">Total</td><td align="char" char="." rowspan="1" colspan="1">110</td><td align="char" char="." rowspan="1" colspan="1">176</td><td align="char" char="." rowspan="1" colspan="1">286</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Sensitivity: 0.52. Specificity 0.88. Positive likelihood ratio: 4.15 (95% CI: 2.70&#x02013;6.38). Negative likelihood ratio: 0.55 (95% CI: 0.45&#x02013;0.67).</p></fn><fn fn-type="other"><p>AD, Alzheimer disease.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>TABLE 4.</label><caption><p>Test Characteristics of Abnormal Background Activity for Diagnosing Any Dementia<xref rid="tblfn1" ref-type="table-fn">*</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Any Dementia<xref rid="tblfn1" ref-type="table-fn">*</xref></td><td rowspan="1" colspan="1">Non Neurologic Disorder</td><td rowspan="1" colspan="1">Total</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Background activity abnormal</td><td align="char" char="." rowspan="1" colspan="1">91</td><td align="char" char="." rowspan="1" colspan="1">22</td><td align="char" char="." rowspan="1" colspan="1">113</td></tr><tr><td rowspan="1" colspan="1">Background activity normal</td><td align="char" char="." rowspan="1" colspan="1">90</td><td align="char" char="." rowspan="1" colspan="1">154</td><td align="char" char="." rowspan="1" colspan="1">244</td></tr><tr><td rowspan="1" colspan="1">Total</td><td align="char" char="." rowspan="1" colspan="1">181</td><td align="char" char="." rowspan="1" colspan="1">176</td><td align="char" char="." rowspan="1" colspan="1">357</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Sensitivity: 0.51. Specificity 0.88. Positive likelihood ratio: 4.07 (95% CI: 2.68&#x02013;6.17). Negative likelihood ratio: 0.56 (95% CI: 0.48&#x02013;0.66).</p></fn><fn fn-type="other" id="tblfn1"><label>*</label><p>Alzheimer disease, vascular dementia, dementia with Lewy bodies, or frontotemporal dementia.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-4"><title>EEG-Based Prediction of Conversion to Dementia for Patients with MCI</title><p>Of the 66 patients initially diagnosed with MCI, 45 had a clinical follow-up (median duration 20 months [IQR: 14&#x02013;33 months]). During this period, 14 patients demonstrated progression of symptoms and fulfilled the criteria for clinical dementia (10 AD, 1 VD, 1 combined AD/VD, and 2 DLB). The EEG characteristics of all MCI cases with clinical follow-up are shown in Fig. <xref rid="F3" ref-type="fig">3</xref>. Those with EEG abnormalities at baseline had a higher chance of converting to dementia compared with those with normal EEG. However, only abnormal BA significantly increased the risk of progression to dementia for patients with MCI (OR 6.1 [95% CI: 1.5&#x02013;24.7]), whereas abnormal response to IPS in the absence of other EEG abnormalities did not significantly increase the risk of conversion (OR 1.4 [95% CI: 0.4&#x02013;4.9]). The likelihood of conversion to dementia was 2.46 (95% CI: 1.29&#x02013;4.68) for abnormal BA versus 0.56 (95% CI: 0.48&#x02013;0.66) for normal BA (Table <xref rid="T5" ref-type="table">5</xref>).</p><fig position="float" id="F3"><label>FIG. 3.</label><caption><p>Amount of patients converted from MCI to dementia based on EEG abnormalities at follow-up (median 20 months). OR for progression to dementia in case of abnormal BA: 6.1 (95% CI: 1.5&#x02013;24.7). OR for progression to dementia in case of abnormal response to IPS: OR 1.4 (95% CI: 0.4&#x02013;4.9). BA, background activity; EEG, electroencephalography; IPS, intermittent photic stimulation; MCI, mild cognitive impairment; OR, odds ratio.</p></caption><graphic xlink:href="jcnp-42-243-g003" position="float"/></fig><table-wrap position="float" id="T5"><label>TABLE 5.</label><caption><p>Likelihood of Conversion From MCI to Dementia Based on Abnormal Background Activity at Clinical Follow-Up (Median Duration 20 months)</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Conversion To Dementia</td><td rowspan="1" colspan="1">Still MCI</td><td rowspan="1" colspan="1">Total</td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Background activity abnormal</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="char" char="." rowspan="1" colspan="1">19</td></tr><tr><td rowspan="1" colspan="1">Background activity normal</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">22</td><td align="char" char="." rowspan="1" colspan="1">26</td></tr><tr><td rowspan="1" colspan="1">Total</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="." rowspan="1" colspan="1">31</td><td align="char" char="." rowspan="1" colspan="1">45</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Sensitivity: 0.71. Specificity 0.71. Positive likelihood ratio: 2.46 (95% CI: 1.29&#x02013;4.68). Negative likelihood ratio: 0.40 (95% CI: 0.17&#x02013;0.95).</p></fn><fn fn-type="other"><p>MCI, mild cognitive impairment.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>The aims of this study were (1) to describe the EEG characteristics in a large cohort from our specialized memory clinic; (2) to assess the diagnostic value of visual EEG assessment and the additional value of IPS, in discriminating different causes of cognitive disorders; and (3) to determine the ability of IPS to discriminate between patients with MCI with and without progression to dementia.</p><p>Our results show that visual assessment of resting-state EEG has diagnostic value in patients with cognitive complaints. Abnormal slowing of BA and decreased PDR peak frequency were the most reliable parameters to distinguish patients with neurodegenerative disease from those with epilepsy or without any neurologic diagnosis. Background activity was normal in 88% of patients without a neurologic disorder, and only 11% to 60% of those with various types of dementia or MCI. Visual interpretation of EEG in the setting of cognitive disorders evaluates the nature of rhythmic BA and the presence of (paroxysmal) slow activity.<sup><xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> The use of EEG in patients with cognitive disorders has been extensively researched, and a similar relationship has previously been demonstrated between increased slow activity on EEG and performance on cognitive tests.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> Several studies have found that EEG patterns differ depending on the underlying cause of cognitive complaints.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> Especially, patients with DLB are known to demonstrate profound EEG abnormalities, irrespective of their age, when compared with patients with AD.<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> Patients with FTD in our study generally had normal BA and PDR. These findings match those from previous studies, which found EEG to be less affected in patients with FTD compared with AD cases, despite marked cognitive deficits.<sup><xref rid="R22" ref-type="bibr">22</xref></sup></p><p>We also studied the added diagnostic value of response to IPS to distinguish severity and different causes of cognitive disorders. Some studies have demonstrated reduced responsiveness in patients with AD compared with healthy controls, especially for higher stimulation frequencies.<sup><xref rid="R14" ref-type="bibr">14</xref>&#x02013;<xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup></p><p>We observed abnormal IPS response in around 46% to 67% of those with MCI or dementia, compared with 30% of participants without a neurologic diagnosis. These differences were smaller than expected based on previous studies and not statistically significant. This might be explained by technical and procedural aspects of IPS testing, which requires cooperation and the sustained attention of the subject.<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup> Although participants may not have had a neurologic cause of their symptoms, they still suffered from cognitive disorders that could have affected their attention levels and the ability to retain focus during IPS, especially in a dim-lit room. In contrast to our study population, many previous studies compared patients with AD with healthy controls without cognitive complaints, who may have had better attention span. Most studies also had relatively small sample sizes. This may explain why in our study abnormal IPS response was not an independent predictor of MCI and only a minor predictor of AD compared with patients without neurologic disorders (Table <xref rid="T6" ref-type="table">6</xref>).</p><table-wrap position="float" id="T6"><label>TABLE 6.</label><caption><p>Correlations Between EEG Parameters and Other Diagnostic Tests in Patients With Memory Complaints</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="2" colspan="1"/><td colspan="2" rowspan="1">Background Activity</td><td colspan="2" rowspan="1">IPS Response</td></tr><tr><td rowspan="1" colspan="1">Spearman &#x003c1;</td><td rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</td><td rowspan="1" colspan="1">Spearman &#x003c1;</td><td rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</td></tr></thead><tbody><tr><td colspan="5" rowspan="1">Imaging</td></tr><tr><td rowspan="1" colspan="1">&#x02003;GCA scale</td><td align="char" char="." rowspan="1" colspan="1">0.36</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="char" char="." rowspan="1" colspan="1">0.30</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;MTA score</td><td align="char" char="." rowspan="1" colspan="1">0.34</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="char" char="." rowspan="1" colspan="1">0.28</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Fazekas scale</td><td align="char" char="." rowspan="1" colspan="1">0.21</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.001</td><td align="char" char="." rowspan="1" colspan="1">0.12</td><td align="char" char="." rowspan="1" colspan="1">0.006</td></tr><tr><td colspan="5" rowspan="1">CSF</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Amyloid-42 level</td><td align="char" char="." rowspan="1" colspan="1">0.30</td><td align="char" char="." rowspan="1" colspan="1">0.013</td><td align="char" char="." rowspan="1" colspan="1">0.20</td><td align="char" char="." rowspan="1" colspan="1">0.1</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>CSF, cerebrospinal fluid; EEG, electroencephalography; GCA, global cortical atrophy; IPS, intermittent photic stimulation; MTA, medial temporal lobe atrophy.</p></fn></table-wrap-foot></table-wrap><p>Third, we studied the prognostic value of EEG in patients with MCI. We found that the presence of abnormal BA on baseline EEG can be used as a prognostic tool to predict the chance of progression to clinical dementia in the future. A diminished or absent response to IPS without accompanying EEG abnormalities had no added value. The prognostic value of EEG in patients with MCI, as demonstrated in this study, is in line with previous research.<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R20" ref-type="bibr">20</xref></sup></p><p>Our results indicate that at initial presentation, abnormal BA is a more useful predictor than a normal EEG. 83% of those with abnormal BA were diagnosed with any form of dementia or MCI, while only 67% with normal BA had no neurologic disorder. Furthermore, when predicting conversion from MCI to dementia, a normal EEG is a more useful predictor. 83% of those with MCI and normal BA did not convert to dementia during follow-up, whereas 56% of those with abnormal BA did. However, patients who have not yet converted might still convert in the future.</p><p>However, prevalence of dementia in our cohort is high, with 37% of participants being diagnosed with &#x0201c;any dementia.&#x0201d; In the general population or general neurologists office, prevalence of dementia will likely be lower. Studies conducted in the emergency department found dementia documented in the medical history of 3% to 6% of presented patients.<sup><xref rid="R25" ref-type="bibr">25</xref></sup> Routine bedside screening tests showed signs of dementia in up to 21.5% of patients older than 70 years admitted to the emergency department.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> With lower prevalence, the usefulness of a normal test result to rule out dementia increases. It is important to note that, with the exception of FTD, all types of dementia and even MCI show abnormal BA in a significant portion of patients (DLB being the most profound), limiting the ability to distinguish between dementia subgroups based on EEG alone.</p><p>There are several strengths to our study. First, we describe a large consecutive cohort comprising of several etiological subgroups of dementia, with a distribution that corresponds well to existing epidemiological data. Furthermore, our reference group consists of actual patients referred for cognitive complaints, but without a neurologic cause for these complaints. This makes our results more applicable to the general population compared with studies that used healthy controls.</p><p>Second, all participants underwent a standardized diagnostic workup, and the final diagnosis was established by a multidisciplinary expert panel, limiting the risk of selection or information bias.</p><p>Third, the emphasis on visual EEG assessment makes for easy interpretation and facilitates the applicability in clinical practice. In recent years, the main focus of many researchers has been on quantitative EEG analysis, such as random forest classifiers and other machine learning algorithms. These studies have demonstrated a high diagnostic yield for patients with DLB and AD, with sensitivity and specificity values around 90%.<sup><xref rid="R27" ref-type="bibr">27</xref>&#x02013;<xref rid="R29" ref-type="bibr">29</xref></sup> However, such techniques are laborsome and require advanced computing skills not possessed by many clinicians. Therefore, they are currently of limited value for the general clinical neurologist. This amplifies the need for visually assessable and reliable EEG parameters in patients with cognitive disorders.</p><p>However, we acknowledge the fact that quantitative analysis of EEG data improves diagnostic accuracy, which is lost in visual analysis. This is a limitation of our study. Moreover, although we do have longitudinal data on a significant portion of patients with MCI and dementia, those in whom no neurologic diagnosis was made were generally excluded from follow-up. Some of these patients may have been erroneously classified as nonneurologic, especially if their symptoms were mild. Further studies should therefore focus on long-term follow-up in a larger cohort of patients with mild symptoms to monitor the rate of progression to MCI or dementia. In addition, repeated EEG measurements at standardized intervals could provide more prognostic parameters for the chance of conversion in this group.</p><p>In conclusion, this study shows that (1) visual EEG assessment has diagnostic and prognostic value and can distinguish patients with memory complaints without underlying neurologic disorder, from patients with MCI or dementia. (2) Abnormal slowing of BA is the most reliable diagnostic parameter for neurodegenerative disease. Although diminished response to IPS is seen more frequently in patients with MCI and dementia compared with nonneurologic disorders, this finding alone cannot support a specific etiological diagnosis. (3) In patients with MCI, normal EEG is associated with a lower likelihood of progression to dementia. Based on these findings, we suggest the use of standard EEG at an early stage in patients with cognitive complaints in whom uncertainty exists regarding the underlying diagnosis.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>The authors thank Dr J. Mulder, clinical neuropsychologist at the Haga hospital, for performing the neuropsychological tests and supplying patient data.</p></ack><fn-group><fn fn-type="COI-statement"><p>The authors have no funding or conflicts of interest to disclose.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><collab>GBD 2019 Dementia Forecasting Collaborators</collab>. <article-title>Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019</article-title>. <source>Lancet Public Health</source>
<year>2022</year>;<volume>7</volume>:<fpage>e105</fpage>&#x02013;<lpage>e125</lpage>.<pub-id pub-id-type="pmid">34998485</pub-id>
</mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><article-title>2022 Alzheimer's disease facts and figures</article-title>. <source>Alzheimers Dement</source>
<year>2022</year>;<volume>18</volume>:<fpage>700</fpage>&#x02013;<lpage>789</lpage>.<pub-id pub-id-type="pmid">35289055</pub-id>
</mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varghese</surname><given-names>S</given-names></name>
<name><surname>Frey</surname><given-names>BN</given-names></name>
<name><surname>Schneider</surname><given-names>MA</given-names></name>
<name><surname>Kapcinski</surname><given-names>F</given-names></name>
<name><surname>De Azevedo Cardoso</surname><given-names>T</given-names></name></person-group>. <article-title>Functional and cognitive impairment in the first episode of depression: a systematic review</article-title>. <source>Acta Psychiatr Scand</source>
<year>2022</year>;<volume>145</volume>:<fpage>156</fpage>&#x02013;<lpage>185</lpage>.<pub-id pub-id-type="pmid">34758106</pub-id>
</mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culpepper</surname><given-names>L</given-names></name>
<name><surname>Lam</surname><given-names>RW</given-names></name>
<name><surname>McIntyre</surname><given-names>RS</given-names></name></person-group>. <article-title>Cognitive impairment in patients with depression: awareness, assessment, and management</article-title>. <source>J Clin Psychiatry</source>
<year>2017</year>;<volume>78</volume>:<fpage>1383</fpage>&#x02013;<lpage>1394</lpage>.<pub-id pub-id-type="pmid">29345866</pub-id>
</mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyketsos</surname><given-names>CG</given-names></name>
<name><surname>Carrillo</surname><given-names>MC</given-names></name>
<name><surname>Ryan</surname><given-names>JM</given-names></name>
<etal/></person-group>. <article-title>Neuropsychiatric symptoms in Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>
<year>2011</year>;<volume>7</volume>:<fpage>532</fpage>&#x02013;<lpage>539</lpage>.<pub-id pub-id-type="pmid">21889116</pub-id>
</mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liedorp</surname><given-names>M</given-names></name>
<name><surname>Van der Flier</surname><given-names>WM</given-names></name>
<name><surname>Hoogervorst</surname><given-names>ELJ</given-names></name>
<name><surname>Scheltens</surname><given-names>P</given-names></name>
<name><surname>Stam</surname><given-names>CJ</given-names></name></person-group>. <article-title>Associations between patterns of EEG abnormalities and diagnosis in a large memory clinic cohort</article-title>. <source>Dement Geriatr Cogn Disord</source>
<year>2009</year>;<volume>27</volume>:<fpage>18</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">19088474</pub-id>
</mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamis</surname><given-names>D</given-names></name>
<name><surname>Sahu</surname><given-names>S</given-names></name>
<name><surname>Treloar</surname><given-names>A</given-names></name></person-group>. <article-title>The utility of EEG in dementia: a clinical perspective</article-title>. <source>Int J Geriatr Psychiatry</source>
<year>2005</year>;<volume>20</volume>:<fpage>1038</fpage>&#x02013;<lpage>1045</lpage>.<pub-id pub-id-type="pmid">16250070</pub-id>
</mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Zande</surname><given-names>JJ</given-names></name>
<name><surname>Gouw</surname><given-names>AA</given-names></name>
<name><surname>Van Steenoven</surname><given-names>I</given-names></name>
<name><surname>Scheltens</surname><given-names>P</given-names></name>
<name><surname>Stam</surname><given-names>CJ</given-names></name>
<name><surname>Lemstra</surname><given-names>AW</given-names></name></person-group>. <article-title>EEG characteristics of dementia with Lewy bodies, Alzheimer's disease and mixed pathology</article-title>. <source>Front Aging Neurosci</source>
<year>2018</year>;<volume>10</volume>:<fpage>190</fpage>.<pub-id pub-id-type="pmid">30018548</pub-id>
</mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H</given-names></name>
<name><surname>Brekelmans</surname><given-names>GJF</given-names></name>
<name><surname>Roks</surname><given-names>G</given-names></name></person-group>. <article-title>The EEG as a diagnostic tool in distinguishing between dementia with Lewy bodies and Alzheimer's disease</article-title>. <source>Clin Neurophysiol</source>
<year>2015</year>;<volume>126</volume>:<fpage>1735</fpage>&#x02013;<lpage>1739</lpage>.<pub-id pub-id-type="pmid">25534493</pub-id>
</mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Zande</surname><given-names>JJ</given-names></name>
<name><surname>Gouw</surname><given-names>AA</given-names></name>
<name><surname>Van Steenoven</surname><given-names>I</given-names></name>
<etal/></person-group>. <article-title>Diagnostic and prognostic value of EEG in prodromal dementia with Lewy bodies</article-title>. <source>Neurology</source>
<year>2020</year>;<volume>95</volume>:<fpage>e662</fpage>&#x02013;<lpage>e670</lpage>.<pub-id pub-id-type="pmid">32636325</pub-id>
</mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="book"><collab>NVN. Dutch Dementia Guideline</collab>. 2021. Available at: <ext-link xlink:href="https://richtlijnendatabasenl/richtlijn/dementie/startpagina_-_dementiehtml" ext-link-type="uri">https://richtlijnendatabasenl/richtlijn/dementie/startpagina_-_dementiehtml</ext-link>. Accessed December 13, 2023.</mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claus</surname><given-names>JJ</given-names></name>
<name><surname>Strijers</surname><given-names>RLM</given-names></name>
<name><surname>Jonkman</surname><given-names>EJ</given-names></name>
<etal/></person-group>. <article-title>The diagnostic value of electroencephalography in mild senile Alzheimer's disease</article-title>. <source>Clin Neurophysiol</source>
<year>1999</year>;<volume>110</volume>:<fpage>825</fpage>&#x02013;<lpage>832</lpage>.<pub-id pub-id-type="pmid">10400195</pub-id>
</mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasteleijn-Nolst Trenit&#x000e9;</surname><given-names>D</given-names></name>
<name><surname>Rubboli</surname><given-names>G</given-names></name>
<name><surname>Hirsch</surname><given-names>E</given-names></name>
<etal/></person-group>. <article-title>Methodology of photic stimulation revisited Updated European algorithm for visual stimulation in the EEG lab</article-title>. <source>Epilepsia</source>
<year>2012</year>;<volume>53</volume>:<fpage>16</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">22091642</pub-id>
</mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kikuchi</surname><given-names>M</given-names></name>
<name><surname>Wada</surname><given-names>Y</given-names></name>
<name><surname>Yoshifumi</surname><given-names>K</given-names></name></person-group>. <article-title>Differences in EEG harmonic driving responses to photic stimulation between normal aging and Alzheimer's disease</article-title>. <source>Clin Electroencephalogr</source>
<year>2002</year>;<volume>33</volume>:<fpage>86</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">12025737</pub-id>
</mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kikuchi</surname><given-names>M</given-names></name>
<name><surname>Wada</surname><given-names>Y</given-names></name>
<name><surname>Takeda</surname><given-names>T</given-names></name>
<name><surname>Oe</surname><given-names>H</given-names></name>
<name><surname>Hashimoto</surname><given-names>T</given-names></name>
<name><surname>Koshino</surname><given-names>Y</given-names></name></person-group>. <article-title>EEG harmonic responses to photic stimulation in normal aging and Alzheimer's disease: differences in interhemispheric coherence</article-title>. <source>Clin Neurophysiol</source>
<year>2002</year>;<volume>113</volume>:<fpage>1045</fpage>&#x02013;<lpage>1051</lpage>.<pub-id pub-id-type="pmid">12088698</pub-id>
</mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wada</surname><given-names>Y</given-names></name>
<name><surname>Nanbu</surname><given-names>Y</given-names></name>
<name><surname>Jiang</surname><given-names>Z-Y</given-names></name>
<name><surname>Koshino</surname><given-names>Y</given-names></name>
<name><surname>Yamaguchi</surname><given-names>N</given-names></name>
<name><surname>Hashimoto</surname><given-names>T</given-names></name></person-group>. <article-title>Electroencephalographic abnormalities in patients with presenile dementia of the Alzheimer type at rest and during photic stimulation</article-title>. <source>Biol Psychiatry</source>
<year>1997</year>;<volume>41</volume>:<fpage>217</fpage>&#x02013;<lpage>225</lpage>.<pub-id pub-id-type="pmid">9018393</pub-id>
</mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Politoff</surname><given-names>AL</given-names></name>
<name><surname>Monson</surname><given-names>N</given-names></name>
<name><surname>Hass</surname><given-names>P</given-names></name>
<name><surname>Stadter</surname><given-names>R</given-names></name></person-group>. <article-title>Decreased alpha bandwidth responsiveness to photic driving in Alzheimer disease</article-title>. <source>Electroencephalogr Clin Neurophysiol</source>
<year>1992</year>;<volume>82</volume>:<fpage>45</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">1370143</pub-id>
</mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonkman</surname><given-names>EJ</given-names></name></person-group>. <article-title>A simple EEG scoring method for senile dementia of the Alzheimer type</article-title>. <source>Electroencephalogr Clin Neurophysiol</source>
<year>1989</year>;<volume>72</volume>:<fpage>34</fpage>&#x02013;<lpage>39</lpage>.</mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>RK</given-names></name>
<name><surname>Chandra</surname><given-names>SR</given-names></name>
<name><surname>Kulkarni</surname><given-names>GB</given-names></name>
<name><surname>Bharath</surname><given-names>RD</given-names></name></person-group>. <article-title>Use of Jonkman et al. Score for visual quantification of electroencephalography as a tool to assess disease severity in cortical dementias</article-title>. <source>Indian J Psychol Med</source>
<year>2017</year>;<volume>39</volume>:<fpage>122</fpage>&#x02013;<lpage>130</lpage>.<pub-id pub-id-type="pmid">28515546</pub-id>
</mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claus</surname><given-names>JJ</given-names></name>
<name><surname>Ongerboer de Visser</surname><given-names>BW</given-names></name>
<name><surname>Walstra</surname><given-names>GJM</given-names></name>
<name><surname>Hijdra</surname><given-names>A</given-names></name>
<name><surname>Verbeeten</surname><given-names>B</given-names></name>
<name><surname>van Gool</surname><given-names>WA</given-names></name></person-group>. <article-title>Quantitative spectral electroencephalography in predicting survival in patients with early Alzheimer disease</article-title>. <source>Arch Neurol</source>
<year>1998</year>;<volume>55</volume>:<fpage>1105</fpage>&#x02013;<lpage>1111</lpage>.<pub-id pub-id-type="pmid">9708961</pub-id>
</mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>CW</given-names></name>
<name><surname>Chen</surname><given-names>HY</given-names></name>
<name><surname>Panegyres</surname><given-names>PK</given-names></name></person-group>. <article-title>Electroencephalography in young onset dementia</article-title>. <source>BMC Neurol</source>
<year>2023</year>;<volume>23</volume>:<fpage>202</fpage>.<pub-id pub-id-type="pmid">37221470</pub-id>
</mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nardone</surname><given-names>R</given-names></name>
<name><surname>Sebastianelli</surname><given-names>L</given-names></name>
<name><surname>Versace</surname><given-names>V</given-names></name>
<etal/></person-group>. <article-title>Usefulness of EEG techniques in distinguishing frontotemporal dementia from Alzheimer's disease and other dementias</article-title>. <source>Dis Markers</source>
<year>2018</year>;<volume>2018</volume>:<fpage>6581490</fpage>.<pub-id pub-id-type="pmid">30254710</pub-id>
</mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drake</surname><given-names>ME</given-names><suffix>Jr</suffix></name>
<name><surname>Shy</surname><given-names>KE</given-names></name>
<name><surname>Liss</surname><given-names>L</given-names></name></person-group>. <article-title>Quantitation of photic driving in dementia with normal EEG</article-title>. <source>Clin Electroencephalogr</source>
<year>1989</year>;<volume>20</volume>:<fpage>153</fpage>&#x02013;<lpage>155</lpage>.<pub-id pub-id-type="pmid">2752585</pub-id>
</mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubboli</surname><given-names>G</given-names></name>
<name><surname>Parra</surname><given-names>J</given-names></name>
<name><surname>Seri</surname><given-names>S</given-names></name>
<name><surname>Takahashi</surname><given-names>T</given-names></name>
<name><surname>Thomas</surname><given-names>P</given-names></name></person-group>. <article-title>EEG diagnostic procedures and special investigations in the assessment of photosensitivity</article-title>. <source>Epilepsia</source>
<year>2004</year>;<volume>45</volume>(<issue>suppl 1</issue>):<fpage>35</fpage>&#x02013;<lpage>39</lpage>.</mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carpenter</surname><given-names>CR</given-names></name>
<name><surname>Bassett</surname><given-names>ER</given-names></name>
<name><surname>Fischer</surname><given-names>GM</given-names></name>
<name><surname>Shirshekan</surname><given-names>J</given-names></name>
<name><surname>Galvin</surname><given-names>JE</given-names></name>
<name><surname>Morris</surname><given-names>JC</given-names></name></person-group>. <article-title>Four sensitive screening tools to detect cognitive dysfunction in geriatric emergency department patients: brief Alzheimer's Screen, Short Blessed Test, Ottawa 3DY, and the caregiver-completed AD8</article-title>. <source>Acad Emerg Med</source>
<year>2011</year>;<volume>18</volume>:<fpage>374</fpage>&#x02013;<lpage>384</lpage>.<pub-id pub-id-type="pmid">21496140</pub-id>
</mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Sullivan</surname><given-names>D</given-names></name>
<name><surname>Brady</surname><given-names>N</given-names></name>
<name><surname>Manning</surname><given-names>E</given-names></name>
<name><surname>O&#x02019;Shea</surname><given-names>E</given-names></name>
<name><surname>O&#x02019;Grady</surname><given-names>S</given-names></name>
<name><surname>O &#x02018;Regan</surname><given-names>N</given-names></name>
<name><surname>Timmons</surname><given-names>S</given-names></name></person-group>. <article-title>Validation of the 6-Item Cognitive Impairment Test and the 4AT test for combined delirium and dementia screening in older Emergency Department attendees</article-title>. <source>Age Ageing</source>
<year>2018</year>;<volume>47</volume>:<fpage>61</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">28985260</pub-id>
</mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dauwan</surname><given-names>M</given-names></name>
<name><surname>van der Zande</surname><given-names>JJ</given-names></name>
<name><surname>van Dellen</surname><given-names>E</given-names></name>
<etal/></person-group>. <article-title>Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease</article-title>. <source>Alzheimers Dement (Amst)</source>
<year>2016</year>;<volume>4</volume>:<fpage>99</fpage>&#x02013;<lpage>106</lpage>.<pub-id pub-id-type="pmid">27722196</pub-id>
</mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cejnek</surname><given-names>M</given-names></name>
<name><surname>Vysata</surname><given-names>O</given-names></name>
<name><surname>Valis</surname><given-names>M</given-names></name>
<name><surname>Bukovsky</surname><given-names>I</given-names></name></person-group>. <article-title>Novelty detection-based approach for Alzheimer's disease and mild cognitive impairment diagnosis from EEG</article-title>. <source>Med Biol Eng Comput</source>
<year>2021</year>;<volume>59</volume>:<fpage>2287</fpage>&#x02013;<lpage>2296</lpage>.<pub-id pub-id-type="pmid">34535856</pub-id>
</mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonanni</surname><given-names>L</given-names></name>
<name><surname>Perfetti</surname><given-names>B</given-names></name>
<name><surname>Bifolchetti</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies</article-title>. <source>Neurobiol Aging</source>
<year>2015</year>;<volume>36</volume>:<fpage>434</fpage>&#x02013;<lpage>445</lpage>.<pub-id pub-id-type="pmid">25129239</pub-id>
</mixed-citation></ref></ref-list></back></article>